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REDUCING SERUM INSULIN AND OVARIAN CYTOCHROME P450c17a
 
 
 
IN POLYCYSTIC OVARY SYNDROME
 
DECREASES IN OVARIAN CYTOCHROME P450c17
 
a
 
 ACTIVITY AND SERUM 
FREE TESTOSTERONE AFTER REDUCTION OF INSULIN SECRETION
IN POLYCYSTIC OVARY SYNDROME
 
J
 
OHN
 
 E. N
 
ESTLER
 
, M.D., 
 
AND
 
 D
 
ANIELA
 
 J. J
 
AKUBOWICZ
 
, M.D.
 
A
 
BSTRACT
 
Background
 
Insulin resistance and increased 
ovarian cytochrome P450c17
 
a
 
 activity are both fea-
tures of the polycystic ovary syndrome. P450c17
 
a
 
, 
which is involved in androgen biosynthesis, has 
both 17
 
a
 
-hydroxylase and 17,20-lyase activities. 
Increased activity of this enzyme results in exag-
gerated conversion of progesterone to 17
 
a
 
-hydroxy-
progesterone in response to stimulation by gonado-
tropin. We hypothesized that hyperinsulinemia 
stimulates ovarian P450c17
 
a
 
 activity.
 
Methods
 
We measured serum steroid concentra-
tions during fasting and the response of serum 
17
 
a
 
-hydroxyprogesterone to leuprolide, a gonado-
tropin-releasing hormone agonist, and performed 
oral glucose-tolerance tests before and after oral ad-
ministration of either metformin (500 mg three times 
daily) or placebo for four to eight weeks in 24 obese 
women with the polycystic ovary syndrome.
 
Results
 
In the 11 women given metformin, 
the mean (
 

 
SE) area under the serum insulin 
curve after oral glucose administration decreased 
from 9303
 

 
1603 to 4982
 

 
911 
 
m
 
U per milliliter per 
minute (56
 

 
10 to 30
 

 
6 nmol per liter per minute) 
(P
 

 
0.004). This decrease was associated with a 
reduction in the basal serum 17
 
a
 
-hydroxyproges-
terone concentration from 135
 

 
21 to 66
 

 
7 ng 
per deciliter (4.1
 

 
0.6 to 2.0
 

 
0.2 nmol per liter) 
(P
 

 
0.01) and a reduction in the leuprolide-stimulat-
ed peak serum 17
 
a
 
-hydroxyprogesterone concentra-
tion from 455
 

 
54 to 281
 

 
52 ng per deciliter 
(13.7
 

 
1.6 to 8.5
 

 
1.6 nmol per liter) (P
 

 
0.01). The 
serum 17
 
a
 
-hydroxyprogesterone values increased 
slightly in the placebo group. In the metformin 
group, the basal serum luteinizing hormone concen-
tration decreased from 8.5
 

 
2.2 to 2.8
 

 
0.5 mlU per 
milliliter (P
 

 
0.01), the serum free testosterone con-
centration decreased from 0.34
 

 
0.07 to 0.19
 

 
0.05 
ng per deciliter (12
 

 
3 to 7
 

 
2 pmol per liter) 
(P
 

 
0.009), and the serum sex hormone–binding 
globulin concentration increased from 0.8
 

 
0.2 to 
2.3
 

 
0.6 
 
m
 
g per deciliter (29
 

 
7 to 80
 

 
21 nmol per li-
ter) (P
 

 
0.001). None of these values changed signif-
icantly in the placebo group.
 
Conclusions
 
In obese women with the polycystic 
ovary syndrome, decreasing serum insulin concen-
trations with metformin reduces ovarian cytochrome 
P450c17
 
a
 
 activity and ameliorates hyperandro-
genism. (N Engl J Med 1996;335:617-23.)
 
©1996, Massachusetts Medical Society.
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HE polycystic ovary syndrome is charac-
terized by anovulation and hyperandro-
genism. It affects approximately 6 percent
of women of reproductive age.
 
1
 
 Insulin re-
sistance accompanied by compensatory hyperinsuli-
nemia is a common feature of the syndrome, and
both obese and nonobese women with the syndrome
are more insulin-resistant and hyperinsulinemic than
age- and weight-matched normal women.
 
2-9
 
 
Hyperinsulinemia may play a pathogenetic part in
hyperandrogenism in women with the polycystic
ovary syndrome by increasing ovarian androgen pro-
duction and decreasing the serum sex hormone–
binding globulin concentration.
 
10-17
 
 Serum free tes-
tosterone concentrations decline in women with the
polycystic ovary syndrome when their insulin secre-
tion is reduced by the administration of diazoxide
 
15
 
or metformin
 
18
 
 or by diet.
 
19,20
 
 Furthermore, the ob-
servation that adolescent girls with hyperandro-
genism have insulin resistance
 
9
 
 suggests that hyper-
insulinemia may play an early and central part in the
pathogenesis of the polycystic ovary syndrome.
Cytochrome P450c17
 
a
 
 is a bifunctional enzyme
that has both 17
 
a
 
-hydroxylase and 17,20-lyase activ-
ities, and it is a key enzyme in the biosynthesis of
ovarian androgens. In ovarian theca cells, P450c17
 
a
 
converts progesterone to 17
 
a
 
-hydroxyprogesterone
through its 17
 
a
 
-hydroxylase activity, and then con-
verts 17
 
a
 
-hydroxyprogesterone to androstenedi-
one through its 17,20-lyase activity. Androstenedi-
one is then converted to testosterone by the enzyme
17
 
b
 
-reductase (Fig. 1).
Many women with the polycystic ovary syndrome
have increased ovarian cytochrome P450c17
 
a
 
 activ-
ity,
 
21,22
 
 as evidenced by increased 17
 
a
 
-hydroxylase
and, to a lesser extent, 17,20-lyase activity, resulting
in excessive ovarian androgen production. In these
women, a hallmark of increased ovarian P450c17
 
a
 
activity is an exaggerated serum 17
 
a
 
-hydroxypro-
gesterone response to stimulation by gonadotropin-
T
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releasing hormone agonists, such as nafarelin,
 
21-23
 
buserelin,
 
24
 
 and leuprolide.
 
25
 
 Whether the increased
ovarian P450c17
 
a
 
 activity in women with the poly-
cystic ovary syndrome is an inherited or an acquired
phenomenon is not known.
We hypothesized that hyperinsulinemia stimulates
ovarian cytochrome P450c17
 
a
 
 activity in women
with the polycystic ovary syndrome (Fig. 1) and that
amelioration of insulin resistance in these women
would return the activity of the enzyme toward nor-
mal. To test this hypothesis, we measured the basal
serum 17
 
a
 
-hydroxyprogesterone concentration and
the serum 17
 
a
 
-hydroxyprogesterone response to the
administration of leuprolide in obese women with
the polycystic ovary syndrome before and after the
administration of metformin, which inhibits the pro-
duction of hepatic glucose and enhances the sensi-
tivity of peripheral tissue to insulin, thereby decreas-
ing insulin secretion.
 
26,27
 
 
 
METHODS
 
Subjects
 
We enrolled 25 women who were 18 to 35 years old, 24 of
whom completed the study. All the women had the polycystic
ovary syndrome, as defined by oligomenorrhea (fewer than six
menstrual periods in the previous year) and hyperandrogenemia
(elevated serum free testosterone concentrations), and were obese
(body-mass index [weight in kilograms divided by the square of the
height in meters], 
 

 
27.5). All had hirsutism, and 15 had acanthosis
nigricans. Two women had each delivered two children, five wom-
en had each delivered one child, and the rest were childless. All had
normal serum prolactin concentrations and normal results on thy-
roid-function tests. Late-onset congenital adrenal hyperplasia was
ruled out by a morning serum 17
 
a
 
-hydroxyprogesterone concen-
tration of less than 200 ng per deciliter (6 nmol per liter). All the
women had findings on ultrasonography of the ovaries that were
consistent with the diagnosis of the polycystic ovary syndrome.
 
28
 
None had taken any medications for at least two months, and none
had diabetes mellitus. Twelve women were randomly assigned to
receive metformin (Glafornil, North Medicamenta, Caracas, Vene-
zuela) and 13 women to receive placebo. The study was approved
by the institutional review board of the Hospital de Clinicas Cara-
cas, and each woman gave informed consent.
 
Study Protocol
 
The women were evaluated during the follicular phase of the
menstrual cycle, as determined by a serum progesterone concen-
tration of less than 2 ng per milliliter (6.4 nmol per liter). On day
1 the women came to the hospital after a 12-hour overnight fast,
and their weight, height, waist-to-hip ratio, and blood pressure
while supine were measured. Blood samples were drawn at 8:30,
8:45, and 9 a.m., and equal volumes of serum were pooled for
the measurement of insulin, glucose, steroids, and sex hormone–
binding globulin. At 9 a.m., 75 g of dextrose (Glycolab, Relab
Laboratory, Caracas, Venezuela) was given orally. Blood samples
were collected for determinations of serum glucose and insulin
concentrations at 60 and 120 minutes.
On day 2 the women ate breakfast at 9 a.m. and then fasted
until 2 p.m., when a leuprolide stimulation test was performed.
 
Figure 1.
 
 Possible Mechanisms of Insulin Stimulation of Ovarian Cytochrome P450c17
 
a
 
 Activity and Androgen Production.
In theca cells, insulin may directly stimulate (plus signs) ovarian cytochrome P450c17
 
a
 
, resulting in increased 17
 
a
 
-
hydroxylase and, to a lesser extent, 17,20-lyase activity. This would lead to increased production of androstenedione,
which is then converted to testosterone by the enzyme 17
 
b
 
-reductase. Alternatively or in conjunction with this, insulin
may stimulate ovarian androgen production indirectly by enhancing the amplitude of serum luteinizing hormone (LH)
pulses, and luteinizing hormone may then stimulate ovarian cytochrome P450c17
 
a
 
 activity.

 ?
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After this test the women took 500 mg of metformin or placebo
orally three times daily. They were instructed not to alter their
usual eating habits, physical activity, or lifestyle during the study.
The women returned for studies four to eight weeks later, after
a low serum progesterone value had confirmed that they were in
the follicular phase of the menstrual cycle. Five women had serum
progesterone values in the postovulatory range after taking met-
formin for four weeks. One of them became pregnant despite
long-standing infertility; she was dropped from the study and her
results were omitted from the analysis. The remaining four women
continued to take metformin and were studied four weeks later
when their serum progesterone values were low. In the placebo
group, one woman had a serum progesterone value in the post-
ovulatory range after four weeks; she was studied again two weeks
later.
 
Leuprolide Stimulation Test
 
After base-line blood samples had been obtained at 2 p.m. on
day 2, leuprolide (10 
 
m
 
g per kilogram of body weight; Lupron,
Abbott Laboratories, Takeda, Japan) was administered subcutane-
ously. Blood samples for the measurement of serum luteinizing
hormone were collected immediately before and 0.5, 1, 16, 20,
and 24 hours after leuprolide was administered. Blood samples
for the measurement of serum 17
 
a
 
-hydroxyprogesterone were
collected immediately before and 16, 20, and 24 hours after leu-
prolide was administered. The women ate an evening meal on day
2 but fasted thereafter until the completion of the test. The early
response of serum luteinizing hormone was determined from
pooled equal volumes of serum taken at 0.5 and 1 hour, and the
late serum luteinizing hormone response from pooled equal vol-
umes of serum taken at 16, 20, and 24 hours. The serum concen-
tration of 17
 
a
 
-hydroxyprogesterone measured immediately be-
fore the administration of leuprolide was considered the basal
value, and the highest serum concentration of 17
 
a
 
-hydroxypro-
gesterone that was measured after the administration of leupro-
lide was considered the peak value.
 
Assays
 
The blood samples were centrifuged immediately, and the se-
rum was stored at 
 

 
20°C until it was assayed. The serum free tes-
tosterone concentration was determined by radioimmunoassay
(Diagnostic Products, Los Angeles). All other hormones and sex
hormone–binding globulin (measured as protein) were assayed as
previously described.
 
15,17,29
 
 To avoid variation among assays, all
samples were analyzed in duplicate in a single assay for each hor-
mone. The intraassay coefficients of variation for the insulin and
luteinizing hormone assays were 5.5 and 1.6 percent, respectively,
and they were less than 10 percent for all the steroid hormone
assays.
 
Statistical Analysis
 
The results are reported as means 
 

 
SE. Within a group, we
compared the results before treatment with those after treatment
by testing for normality with the Wilk–Shapiro test and using
Student’s two-tailed paired t-test or the Wilcoxon signed-rank
test. Comparisons between groups were made with Student’s two-
tailed unpaired t-test or the Mann–Whitney rank-sum test.
We analyzed the responses of serum glucose and insulin to the
oral administration of glucose and the responses of serum lutein-
izing hormone and 17
 
a
 
-hydroxyprogesterone to the administra-
tion of leuprolide by calculating the areas under the response
curves by the trapezoidal rule using absolute values.
 
RESULTS
 
Base-Line Characteristics
 
The women in the metformin and placebo groups
did not differ significantly in age, body-mass index,
waist-to-hip ratio, blood pressure, or serum concen-
trations of sex steroids or sex hormone–binding glob-
ulin at base line (Table 1). They also did not differ at
base line in serum insulin or glucose values measured
during fasting, insulin or glucose responses after oral
glucose administration, or basal or leuprolide-stimu-
lated serum 17
 
a
 
-hydroxyprogesterone values (Table 1
and Fig. 2). The base-line serum luteinizing hormone
concentration was higher in the metformin group
than in the placebo group (8.5
 
2.2 vs. 3.70.7
mIU per milliliter; P0.04) (Fig. 3).
Anthropometric Variables
The body-mass index did not change significant-
ly during the study in either group. The waist-to-hip
ratio decreased slightly in the metformin group
(P0.02) but did not change substantially in the
placebo group. There was no significant change in
diastolic or systolic blood pressure in either group.
Serum Insulin and Glucose Profiles
In the metformin group, the mean serum insulin
concentration measured during fasting decreased
from 173 to 92 mU per milliliter (10218 to
5412 pmol per liter) (P0.03), and the area under
the serum insulin curve decreased from 93031603
to 4982911 mU per milliliter per minute (5610
to 306 nmol per liter per minute) (P0.004) (Ta-
ble 1). Neither of these values changed significantly
in the placebo group. The serum glucose concen-
tration in fasting women did not change significantly
in either group. The area under the serum glucose
curve increased in the placebo group (P0.03) but
did not change substantially in the metformin group. 
Responses of Serum Luteinizing Hormone to Leuprolide
The basal serum luteinizing hormone concentra-
tion decreased from 8.52.2 to 2.80.5 mIU per
milliliter (P0.01) in the metformin group but did
not change significantly in the placebo group (Fig.
3). The early serum luteinizing hormone responses to
leuprolide were lower after the administration of met-
formin than at base line (17.02.5 vs. 40.811.9
mIU per milliliter, P0.01). The late serum lutein-
izing hormone responses were slightly but not sig-
nificantly lower after the administration of metfor-
min (P0.26). In contrast, in the placebo group
the basal serum luteinizing hormone concentrations
and the early and late serum luteinizing hormone
responses to leuprolide were virtually identical at
base line and after the administration of placebo
(Fig. 3).
Serum 17a-Hydroxyprogesterone Responses
In the metformin group, the mean basal serum
17a-hydroxyprogesterone concentration decreased
by 51 percent, from 13521 to 667 ng per deci-
liter (4.10.6 to 2.00.2 nmol per liter) (P0.01),
but it did not change significantly in the placebo
The New England Journal of Medicine 
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group (Fig. 2). Similarly, in the metformin group the
peak serum 17a-hydroxyprogesterone concentra-
tion after leuprolide administration decreased from
45554 to 28152 ng per deciliter (13.71.6 to
8.51.6 nmol per liter) (P0.01), and the area un-
der the serum 17a-hydroxyprogesterone curve de-
creased from 7848945 to 4592766 ng per deci-
liter per hour (23729 to 13923 nmol per liter
per hour) (P0.004), whereas these values increased
slightly in the placebo group (Fig. 2). The change
in the area under the serum 17a-hydroxyprogeste-
rone curve in the metformin group differed signifi-
cantly from that in the placebo group (3256180
vs. 912105 ng per deciliter per hour [9827
vs. 2810 nmol per liter per hour]) (P0.001),
and the area under the serum 17a-hydroxyproges-
terone curve was significantly less after metformin
administration than after placebo administration
(4592766 vs. 6949685 ng per deciliter per hour
[13921 vs. 21021 nmol per liter per hour])
(P0.02).
Serum Sex Steroids
The administration of metformin was associated
with a 44 percent decrease in serum free testosterone
concentrations, from 0.340.07 to 0.190.05 ng per
deciliter (122 to 72 pmol per liter) (P0.009),
and a threefold increase in serum sex hormone–bind-
ing globulin concentrations, from 0.80.2 to 2.30.6
mg per deciliter (297 to 8021 nmol per liter)
(P0.001) (Table 1). These values did not change sig-
nificantly in the placebo group. The serum concentra-
tions of the other measured steroids did not change
substantially in either group.
DISCUSSION
In these women with the polycystic ovary syn-
drome, the administration of metformin reduced the
*The mean (SE) length of administration was 424 days in the metformin group and 322 days in the placebo
group. Plus–minus values are means SE. To convert values for insulin to picomoles per liter, multiply by 6.0; to convert
values for glucose to millimoles per liter, multiply by 0.056; to convert values for progesterone to nanomoles per liter,
multiply by 3.2; to convert values for testosterone to picomoles per liter, multiply by 34.7; to convert values for andro-
stenedione to picomoles per liter, multiply by 34.9; to convert values for 17b-estradiol to picomoles per liter, multiply
by 36.7; to convert values for dehydroepiandrosterone sulfate to micromoles per liter, multiply by 0.027; and to convert
values for sex hormone–binding globulin to nanomoles per liter, multiply by 34.7. The normal ranges for ovulatory wom-
en are as follows: insulin, 5 to 20 mU per milliliter; progesterone, 2.0 ng per milliliter during the follicular phase; tes-
tosterone, 22 to 70 ng per deciliter; free testosterone, 0.06 to 0.19 ng per deciliter; androstenedione, 66 to 300 ng per
deciliter; 17b-estradiol, 1 to 20 ng per deciliter (early follicular to midfollicular phase); dehydroepiandrosterone sulfate,
35 to 430 mg per deciliter; and sex hormone–binding globulin, 0.6 to 4.0 mg per deciliter.
†P0.02 for the comparison with base line.
‡P0.03 for the comparison with base line.
§Values are for the area under the curve (AUC) during an oral glucose-tolerance test.
¶P0.004 for the comparison with base line.
P0.009 for the comparison with base line.
**P0.001 for the comparison with base line.
TABLE 1. CHARACTERISTICS OF WOMEN WITH THE POLYCYSTIC OVARY SYNDROME AT BASE LINE 
AND AFTER THE ADMINISTRATION OF METFORMIN OR PLACEBO FOR FOUR TO EIGHT WEEKS.*
CHARACTERISTIC METFORMIN GROUP (N11) PLACEBO GROUP (N13)
BASE LINE AFTER METFORMIN BASE LINE AFTER PLACEBO
Age (yr) 291 — 292 —
Body-mass index 34.11.5 34.11.3 35.21.9 35.21.9
Waist-to-hip ratio 0.860.01 0.850.02† 0.860.01 0.870.01
Blood pressure (mm Hg)
Systolic
Diastolic
1282
871
1272
831
1324
882
1343
882
Fasting serum insulin (mU/ml) 173 92‡ 285 315
AUC for insulin (mU/ml/min)§ 9,3031603 4,982911¶ 9,0221046 9,9701119
Fasting serum glucose (mg/dl) 792 762 834 863
AUC for glucose (mg/dl/min)§ 11,382406 11,189679 12,224524 13,448526‡
Serum progesterone (ng/ml) 0.80.1 0.80.1 1.00.2 0.80.1
Serum testosterone (ng/dl) 9017 6814 6914 8111
Serum free testosterone (ng/dl) 0.340.07 0.190.05 0.210.05 0.270.06
Serum androstenedione (ng/dl) 32429 28925 25920 27218
Serum 17b-estradiol (ng/dl) 10.61.3 9.01.1 8.00.9 8.90.7
Serum dehydroepiandrosterone sulfate (mg/dl) 17622 19621 17019 18018
Serum sex hormone–binding globulin (mg/dl) 0.80.2 2.30.6** 0.80.1 0.90.1
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Figure 2. Mean (SE) Serum 17a-Hydroxyprogesterone Con-
centrations in Women with the Polycystic Ovary Syndrome at
Base Line and after the Administration of Metformin or Place-
bo for Four to Eight Weeks. 
Metformin was administered for a mean (SE) of 424 days,
and placebo for 322 days. The women were studied before
and after the administration of leuprolide (10 mg per kilogram).
To convert values for 17a-hydroxyprogesterone to nanomoles
per liter, multiply by 0.03. AUC denotes area under the curve.
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serum insulin concentration during fasting and the
insulin response to oral glucose administration. Con-
comitantly, ovarian cytochrome P450c17a activity
decreased, as demonstrated by a substantial reduc-
tion in the response of serum 17a-hydroxyprogeste-
rone to the administration of leuprolide (to increase
luteinizing hormone secretion). The reduction in
P450c17a activity was accompanied by a decline in
the serum free testosterone concentration. These
findings suggest that increased ovarian cytochrome
P450c17a activity in women with the polycystic
ovary syndrome is due to stimulation by insulin (Fig.
1) and can be reversed by reducing the secretion of
insulin. We intentionally did not screen the women
for the presence of insulin resistance or increased
P450c17a activity so that our results would be ap-
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plicable to unselected women with the polycystic
ovary syndrome.
We cannot exclude the possibility that the decrease
in ovarian P450c17a activity resulted from the re-
duction in serum free testosterone or a direct action
of metformin, but these possibilities seem remote.
Hyperandrogenism is a consequence of increased
ovarian P450c17a activity and is therefore unlikely
to be the cause of the stimulated enzyme activity.
Hyperandrogenism in women with the polycystic
ovary syndrome is ameliorated by diazoxide15 — a
drug structurally unrelated to metformin that sup-
presses insulin release and worsens glucose tolerance
— and by diet.19,20 The common factor among these
diverse therapies appears to be the reduction in se-
rum insulin concentrations. Because diazoxide is not
known to alter insulin sensitivity yet lowers serum
testosterone concentrations in women with the poly-
cystic ovary syndrome,15 hyperandrogenism in such
women appears to be related to hyperinsulinemia it-
self and not to insulin resistance; moreover, insulin
stimulates ovarian androgen production in vitro.11-14
The recent report by Moghetti et al.30 that hyperin-
sulinemia may stimulate cytochrome P450c17a ac-
tivity in another steroidogenic tissue of women with
the polycystic ovary syndrome — namely, the adrenal
glands — further supports our findings.
The early and late serum luteinizing hormone re-
sponses to leuprolide after the administration of pla-
cebo were almost identical to those at base line.
In contrast, the administration of metformin was
associated with decreased basal and leuprolide-stim-
ulated serum luteinizing hormone concentrations.
These observations raise the possibility that insulin
enhances both the endogenous (basal) and the ex-
ogenous (leuprolide-stimulated) release of luteiniz-
ing hormone mediated by gonadotropin-releasing
hormone and that increased ovarian cytochrome
P450c17a activity in women with the polycystic
ovary syndrome may be related to an insulin-induced
abnormality in the dynamics of gonadotropin secre-
tion rather than (wholly or partially) to direct stim-
ulation of ovarian steroidogenesis by insulin (Fig.
1). Insulin receptors have been identified in human
pituitary tissue,31 and insulin augments the release
of luteinizing hormone by cultured rat pituitary
cells.32 
The secretion of luteinizing hormone is often in-
creased in women with the polycystic ovary syn-
drome,33 and the diurnal changes in the serum con-
centrations of luteinizing hormone and insulin in
these women follow a similar time course.34 Prelim-
inary studies suggest that insulin enhances the am-
plitude of serum luteinizing hormone pulses but not
their frequency in obese women with the polycystic
ovary syndrome (unpublished data). An alternative
possibility is that the reduction in luteinizing hor-
mone secretion in the women we studied was due to
a decrease in the concentration of circulating andro-
gens. However, raising serum androgen concentra-
tions by parenteral administration in normal women35
or women with the polycystic ovary syndrome36
does not stimulate the secretion of luteinizing hor-
mone. Finally, some of the women in our study who
received metformin ovulated, and ovulation itself may
influence the dynamics of gonadotropin secretion.37
However, in our study the results in the women who
had ovulated and those who had not were similar.
The metformin-induced reduction in insulin se-
cretion was associated with substantial decreases in
serum free testosterone concentrations and increases
in serum sex hormone–binding globulin concentra-
tions. In women with the polycystic ovary syndrome,
insulin stimulates ovarian androgen production11-15
and lowers serum sex hormone–binding globulin
concentrations.16,17 Our findings, and those of an
uncontrolled trial18 of metformin in women with the
polycystic ovary syndrome, support these observa-
tions. In contrast, Crave et al. found that neither se-
rum testosterone nor sex hormone–binding globulin
concentrations changed in women with the polycys-
tic ovary syndrome who were treated with a hypo-
caloric diet and metformin for four months.38 The
reasons for the discrepancies among these studies are
unknown.
In summary, our findings suggest that two fea-
tures of the polycystic ovary syndrome — hyperin-
sulinemic insulin resistance and increased ovarian cy-
tochrome P450c17a activity — are pathogenetically
linked, and that hyperinsulinemia stimulates this en-
zyme either directly or indirectly by increasing go-
nadotropin secretion (Fig. 1). The ability of insulin to
stimulate ovarian cytochrome P450c17a is probably
limited to women with the polycystic ovary syndrome
and may be a heritable abnormality, since many other
obese women who also are hyperinsulinemic have
neither hyperandrogenism nor hyperresponsiveness
to gonadotropin-releasing hormone.22 The clinical
implication of these results is that therapeutic meas-
ures directed at lowering insulin secretion in women
with the polycystic ovary syndrome should amelio-
rate their hyperandrogenism.
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